| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -11,772,288 | -6,721,204 |
| Depreciation and amortization | 381,177 | 267,817 |
| Stock-based compensation expense | 605,355 | 538,223 |
| Fair value adjustment on warrants | 3,810,278 | 1,062,818 |
| Accounts and other receivables | -690,214 | -717,335 |
| Inventory | 7,626 | 16,363 |
| Prepaid expenses and other assets | 30,331 | -29,706 |
| Accounts payable | -46,550 | 182,526 |
| Accrued expenses | -414,175 | -350,688 |
| Unearned revenue | 13,511 | 0 |
| Operating lease right-of-use asset | -1,156 | -849 |
| Net cash used in operating activities | -6,769,279 | -4,288,981 |
| Proceeds from exercised stock options | - | 0 |
| Purchase of property and equipment | 60,567 | 64,213 |
| Proceeds from loans payable | - | 0 |
| Net cash used in investing activities | -60,567 | -64,213 |
| Proceeds from issuance of common stock from direct offering | 9,271,534 | 2,798,354 |
| Proceeds from exercise of warrants | 4,813,742 | 1,558,576 |
| Proceeds from issuance of convertible preferred stock | 990,000 | - |
| Payment of offering costs for financing activities | 1,418,459 | - |
| Payment on loans payable, net | 11,795 | 112,951 |
| Principal repayments on finance leases | 251,272 | 193,241 |
| Net cash provided by financing activities | 13,393,750 | 4,050,738 |
| Net increase (decrease) in cash and cash equivalents | 6,563,904 | -302,456 |
| Cash and cash equivalents at beginning of period | 1,105,291 | - |
| Cash and cash equivalents at end of period | 7,669,195 | - |
bioAffinity Technologies, Inc. (BIAF)
bioAffinity Technologies, Inc. (BIAF)